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A novel mechanism linking memory 
stem cells with innate immunity in 
protection against HIV-1 infection
Yufei Wang1, Trevor Whittall  1, Stuart Neil2, Gary Britton1, Mukesh Mistry1, Supachai Rerks-
Ngarm3, Punnee Pitisuttithum4, Jaranit Kaewkungwal4, Sorachai Nitayaphan5, Xuesong Yu6, 
Alicia Sato6, Robert J. O’Connell7, Nelson L. Michael7, Merlin L. Robb7,8, Jerome H. Kim7,9 & 
Thomas Lehner1
HIV infection affects 37 million people and about 1.7 million are infected annually. Among the phase 
III clinical trials only the RV144 vaccine trial elicited significant protection against HIV-1 acquisition, 
but the efficacy and immune memory were inadequate. To boost these vaccine functions we studied 
T stem cell memory (TSCM) and innate immunity. TSCM cells were identified by phenotypic markers 
of CD4+ T cells and they were further characterised into 4 subsets. These expressed the common IL-2/
IL-15 receptors and another subset of APOBEC3G anti-viral restriction factors, both of which were 
upregulated. In contrast, CD4+ TSCM cells expressing CCR5 co-receptors and α4β7 mucosal homing 
integrins were decreased. A parallel increase in CD4+ T cells was recorded with IL-15 receptors, 
APOBEC3G and CC chemokines, the latter downmodulating CCR5 molecules. We suggest a novel 
mechanism of dual memory stem cells; the established sequential memory pathway, TSCM →Central 
→Effector memory CD4+ T cells and the innate pathway consisting of the 4 subsets of TSCM. Both 
pathways are likely to be activated by endogenous HSP70. The TSCM memory stem cell and innate 
immunity pathways have to be optimised to boost the efficacy and immune memory of protection 
against HIV-1 in the clinical trial.
The global human immunodeficiency virus (HIV-1) pandemic continues, and an effective vaccine has so far not 
been produced. A number of HIV phase III vaccine trials have been carried out but only the RV144 prime-boost 
trial achieved significant, though limited protection of 31.2% against HIV acquisition1. The vaccine induced 
mostly antibody binding and ADCC (antibody dependent cytotoxicity). Investigations into the immune corre-
lates of protection showed an inverse correlation between binding IgG antibody levels to the HIV-1gp120 variable 
regions 1 and 2 (V1V2) and the risk of HIV-1 infection2–4. A surprising finding was that IgA antibodies against 
envelope were directly associated with lack of protection, possibly by blocking certain HIV specific IgG effec-
tor functions5. A comprehensive functional analysis of vaccine-induced CD4+ T cell responses demonstrated 
polyfunctional antigen-specific cellular immune responses; CD154 expression, IL-2, IL-4, IFN-γ, and TNF-α 
cytokines, which were inversely correlated to HIV-1 infection4, 6, 7. The CD4+ T cells directed against HIV-1 enve-
lope2–4 were mostly HIV-env specific CD45RO+ CCR7− effector memory T cells4.
A robust immunological memory is critical for the function of any vaccine and may have been inadequate in 
the RV144 vaccine. The efficacy of protection of HIV-1 acquisition decreased from 60% in the 1st year, to 36% 
in the 2nd and 32.3% in the 3rd year8, despite expressing significant Env-specific CD4+ effector memory T cells4. 
This led us to examine long-term T stem cell memory (TSCM) cells, defined by expressing CD45RO− CCR7+ 
CD62L+ CD95+ T cell phenotypic markers9, 10. TSCM cells were studied by polychromatic flow cytometry9, 10 
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and have been reported in mice, NHP (non-human primates) and humans, but this is the first investigation of 
the effect of vaccination on TSCM. We hypothesised that there are subsets of CD4+ TSCM cells associated with 
innate immune responses to the RV144 vaccine and we analysed these cells in relation to the central and effector 
memory T cells.
HIV-1 infection is inhibited by two well defined naturally occurring mechanisms. Homozygous 32-bp 
CCR5 deletion11, 12 and allo-immunity13–16 have been demonstrated by HIVgp140/HSP70 immunization and 
allo-immunization of humans and NHP, inducing CC chemokines, which downmodulate CCR514–16. A third type 
of natural immunity has been identified in sooty mangabeys, which acts as a natural host for SIV infection, in 
which high concentrations of SIV persist, the CD4 cell count does not fall and the animals remain healthy without 
developing AIDS17. The key feature is a low level of cell surface expression of CCR5 in long-lived CD4+ T central 
and memory TSCM but high level of CCR5 in the effector memory cells17. Similar changes have been described 
in non-progressing HIV-1 infected people, who remain healthy despite high viral load and express low levels of 
HIV DNA in CD4+ TSCM18. Recently non-progressing HIV-1 infected children also seem to share the features 
found in SIV infected sooty mangabeys19. These immune mechanisms may play a significant role in early control 
of HIV infection by affecting the efficiency of mucosal HIV transmission and dissemination as well as influencing 
acute viral replication20, 21.
Innate immunity may be manifested by upregulation of CC chemokines, eliciting downmodulation of CCR5 
co-receptors, which inhibits pre-entry HIV-122–25. This is often followed by increase in innate retroviral restric-
tion factors, such as A3G and tetherin, inhibiting post-entry HIV-125, 26. A number of intracellular host-encoded 
HIV-1 restriction factors have been described, blocking viral fusion by interfering with viral RNA reverse tran-
scription and post-integration restriction and adherence. Some of the most significant restriction factors of HIV 
replication are APOBEC 3 G (A3G) or F protein27, TRIM5-α28, 29, Tetherin30, 31, SAMHD132 and MX233, 34, which 
are largely stimulated by type 1 interferons (IFN). Mucosal immunization of NHP with HSP70 linked to SIV 
antigens may also upregulate A3G35 and inhibit Vif mediated ubiquitination of A3G36.
In this study of the RV144 HIV-1 vaccine trial, in which ALVAC-HIV and AIDSVAX B/E were used we found 
significant increases in CD4+ TSCM cells, which were further differentiated into CD122+, A3G, CCR5+ and α4β7 
expressing subsets of cells. Significantly, enhanced early innate immunity may offer initial resistance to infection 
and also boost subsequent HIV-1-specific adaptive cellular and antibody responses25, 26, 35, 37, 38. We suggest a novel 
dual pathway of CD4+ memory stem cells; the established sequential memory pathway 1 TSCM →CMC →EMC, 
and innate pathway 2, in which TCSM generate subsets of IL-2/IL-15 receptors (CD122), A3G, CCR5 and α4β7 
innate immune cells. The mechanism of this dual memory stem cells and innate immunity is likely to be activated 
by endogenous HSP70, which is the hallmark of cellular stress.
Results
The effect of vaccination on CD4+ and CD8+ T memory stem cells. CD4+ and CD8+ T cells have 
been studied in the RV144 trial4 and demonstrated mostly CD4 CD45RO+ CCR7− effector memory T cells39, 
responding to epitopes within the V2 region of the HIV-1 envelope. Here we have asked 2 related questions, 1) 
does immunization with the vaccine elicit CD4 and/or CD8 TSCM. 2) Do the TSCM express specific phenotypic 
markers. We have initially examined PBMC taken before immunization and 2 and 28 weeks after the last immu-
nization. We found an increase in the population of CD4+ CD45RO− CCR7+ CD95+ TSCM cells (2.33 ± 0.27) 
before vaccination to 2.86 ± 0.43 (p = 0.12) at 2 weeks and (3.12 ± 0.36 p = 0.018) at 28 weeks after the last vac-
cination (Fig. 1A). CD8+ TSCM cells were lower than those of CD4+ TSCM before vaccination and though they 
increased slightly 2 weeks after vaccination (p = 0.08), they fell to the pre-vaccination level 28 weeks after vacci-
nation (Fig. 1B). However, the possibility will have to be considered that the vaccine might favour only the CD4+ 
and elicits limited CD8+ TSCM. The CD8+ T cells were not studied further in this paper.
To find out if the TSCM were elicited by HIVgp140 or the Canary pox/ALVAC stress component of the vac-
cine, cells were taken after immunization and stimulated in vitro with HIVgp140, which showed a negligible 
increase in TSCM (Fig. 1C), compared with recombinant IL-15 or microbial HSP70. This suggests that HIVgp140 
was not critical in the induction of CD4+ TSCM, unlike IL-15 and HSP70. We repeated the CD4+ TSCM assays 
in further samples from 10 vaccinees and 7 placebo controls, pre- and 28 weeks post-immunization (Fig. 1D), 
This confirmed significant increase of CD4+ TSCM 28 weeks after the last immunization in the vaccinated cohort 
(p = 0.004, Fig. 1D). However, CCR7+ central, CCR7− effector memory and naïve CD4+ CD45RO− T cells from 
the same samples of blood showed no significant difference after vaccination (Fig. 1E–G). Identification of TSCM 
and gating are shown in Fig. 1H. Placebo controls showed no significant difference in TSCM (p = 0.34).
The effect of vaccination on TSCM cells expressing CD122. The CD4+ TSCM were then studied to 
find out whether they express CD122, the β chain for IL-2 and IL-15 receptors, which might be activated by maIL-
15 induced by the Canary pox, stress-mediated iHSP7040, 41 and IL-2 is produced by TSCM10. Significant increases 
in CD4+ CD122+ TSCM were found 28 weeks after vaccination (p = 0.002) and in CD45RO+ CCR7+ central 
memory T cells (p = 0.033), but not in CD45RO+CCR7− effector memory or CD4+ CD45RO− naive T cells 
(Fig. 2A). An illustration of flow cytometry is presented in Fig. 2E. The control placebo treated cohort showed 
no significant change in any of the 4 corresponding placebo control CD4+ T cells (Fig. 3A,B). Altogether, CD122 
common receptors of IL-15 and IL-2 are likely to be elicited by an increase in maIL-15, through stress generated 
iHSP70, which activate and expand TSCM.
Effect of the vaccine on the expression of APOBEC 3 G in TSCM. A3G is one of many restriction 
factors identified in TSCM9. We have studied the expression of A3G in CD4+ TSCM, before and after vaccination 
in relation to the persistence of memory and to T cell subsets42. A significant increase of A3G in CD4+ TSCM was 
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found 28 weeks after vaccination (p = 0.012, Fig. 2B) and similarly to CD122 was significant in central (p = 0.017) 
but not effector memory (p = 0.20) or naïve CD4+ T cells. Flow cytometry illustration of A3G in TSCM and other 
T cell subsets are presented (Fig. 2F). Placebo controls failed to show significant changes (Fig. 3C).
Effect of vaccination on the expression of CCR5 in CD4+ TSCM. In contrast to CD122 and A3G 
TSCM subsets, CD4+ TSCM expressing CCR5 were significantly decreased (p = 0.004, Fig. 2C) as were the cen-
tral memory T cells (p < 0.001) but again not the effector or naïve CD4+ T cells. Flow cytometry is demonstrated 
in Fig. 2E. Corresponding studies were carried out with TSCM expressing CXCR4, which function as receptors 
for X4 HIV-1, but these failed to show any change (Supl. Fig. 1). The decrease in CCR5+ CD4+ T cells express-
ing coreceptors for R5 HIV-1, may contribute to the protective mechanism. It is noteworthy that the CD45RO+ 
CCR7+ central memory T cells followed a similar pattern to that of TSCM cells, with the CD122, A3G and 
CCR5+ TSCM, (Fig. 2A–C). The placebo controls failed to show significant changes (Fig. 3D).
Effect of the vaccine on the expression of α4β7 integrin. The α4β7 integrin binds HIV-1 gp140 
of CD4+ CCR5+ T cells, which home to the lamina propria of mucosal tissue of the gut and interacts with the 
addresin adhesion molecule on high endothelial venules. α4β7 was significantly decreased in CD4+ TSCM 
(p = 0.002), but not in the central or effector memory T cells (Fig. 2D,E), so its mucosal homing function may be 
diminished.
Investigation of stress-induced HSP70 in the induction of CD4+ TSCM. To find out if the 
prime-boost vaccine of canary-pox (ALVAC-HIV-1, vCP1521) AIDSVAX B/E and Alum may have acted as stress 
agents we assayed iHSP70 in DC, which is a hallmark of cellular stress43–45. In a further cohort of 11 subjects 
we confirmed a significant increase in the post-immunization CD4+ TSCM (Fig. 4A, p = 0.01), upregulation of 
iHSP70 in TSCM or DC (Fig. 4B,C, p = 0.005) and IL-15 in DC (Fig. 4D, p = 0.03), but not in the placebos (data 
not shown). Microbial HSP70 was then used in vitro and confirmed that stress upregulates CD4+ TSCM, but 
significance was reached only in the post-immunised CD4+ TSCM samples (p = 0.033, Fig. 4G,H). Gating and 
the flow cytometry illustration of DC identification, IL-15 and iHSP70 expression in DC and iHSP70 in TSCM 
are presented in Fig. 4E,F. To confirm that iHSP70 is responsible for the increase in CD4+ TSCM, the cells were 
treated with PES (phenylethynesulfonamide), a small molecular inhibitor of iHSP70 function46. This showed 
Figure 1. Identification of TSCM CD45RO− CCR7+ CD95+ CD4+ and CD8+ T cells. (A) CD4+ TSCM and (B) 
CD8+ TSCM cells pre- immunization, 2 and 28 weeks after the last immunization (n = 12–18), all from different 
immunized subjects. (C) The specificity of TSCM was examined by in vitro stimulation with HIVgp140 and 
compared with recombinant IL-15 and microbial (m) HSP70. (D) Shows significant increase in CD4+ TSCM 28 
weeks after the last immunization in the vaccinated cohort, but not in the CCR7+ central (CM), CCR7- effector 
memory (EM) or naïve CD4+ T cells (n = 10 in each group, (E,F,G). (H) Identification of TSCM and gating.
www.nature.com/scientificreports/
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a significant dose-dependent inhibition in post-immunised CD4+ TSCM, if stimulated in vitro with mHSP70 
(Fig. 4I). These data are consistent with HSP70 induced cellular stress playing an important role in expanding and 
potentially self-replicating CD4+ TSCM.
Characterisation of CD4+ TSCM by the production of cytokines. Further characterisation of the 
CD4+ TSCM by cytokines was pursued by intra-cellular staining. This showed that IFN-γ and IL-2 were signifi-
cantly increased when stimulated with HIVgp140 of the post-immunized cells (p = 0.01 and p = 0.05, respectively 
Fig. 4J), whilst IL-17 was significantly decreased (p = 0.039). However, TNFα showed only a small increase on 
treatment with HIVgp140 (p = 0.2, Supl. Fig. 2A). As expected, the control anti-CD3 antibody stimulated, signif-
icantly greater cytokine response with IFN-γ, IL-2 and TNFα (p ≤ 0.001, Supl. Fig. 2A,B). The interpretation of 
these results is based on our demonstration that stress upregulates T bet and RORγt transcription factors, whereas 
FoxP3 is decreased, resulting in an overall enhanced Th1 polarisation40. This may enhance HIV-1 persistence 
during antiretroviral treatment47. However, the present human immunization results suggest that there is a diver-
gence between Th1 (IFN-γ and IL-2) and Th17 (IL-17) cytokines and it is not clear which is the dominant partner.
Pre- and post- immunization correlations between CD4+ TSCM and iHSP70, CD122, A3G, CCR5 
and α4β7 subsets of TSCM. A major objective of this work was to find out which aspect of immune mem-
ory was not expressed optimally. To this end we have carried out pre- and post- immunization correlation anal-
yses between CD4+ TSCM and its 4 subsets (Suppl. Fig. 3). These analyses failed to show significant correlations 
but only a direct trend of TSCM with HSP70 in DC from pre- (r = 0.37) to post-immunization (r = 0.54) and 
similarly with HSP70 in TSCM (0.45 to 0.56) respectively, consistent with stress-mediated HSP70 involvement in 
CD4+ TSCM generation. Interestingly, CD122 TSCM showed no correlation in the pre- or post- immunization 
cells (Suppl. Fig. 3C). However, A3G showed a reversal from an inverse trend of A3G before (r = −0.64, Suppl. 
Fig. 3D) to a slight direct trend after immunization (r = 0.02), which is a desirable direction of inhibition of 
HIV-1.
CCR5 subset of CD4+ TSCM cells showed conversion from a direct trend before (r = 0.19, Suppl. Fig. 3E) 
to an inverse trend (r = −0.46) after immunization with CD4 TSCM. Finally, α4β7 also converted, from a 
direct (r = 0.56, Suppl. Fig. 3F) to an inverse trend (r = −0.15), respectively. These results are consistent with 
Figure 2. The effect of vaccination on the expression of (A) CD122, (B) A3G, (C) CCR5 and (D) intracellular 
α4β7 in CD4+ TSCM, central, effector memory and naive CD4+ T cells, before and 28 weeks after the last 
vaccination (n = 9, except (B) n = 12) from different subjects. However, the comparison between the different 
memory and naïve cells was with the same 9 samples). (E,F) Gating and identification of CD122, CCR5 α4β7 
and A3G TSCM cells.
www.nature.com/scientificreports/
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Figure 3. The effect of placebo on (A) TSCM, central, effector memory and naïve CD4+ T cells, (B) CD122, (C) 
A3G and (D) CCR5 in the corresponding CD4+ T cell subsets (n = 7) samples from different subjects but the 
comparison was as in Fig. 2. Gating and identification of these subsets of cells is similar to those illustrated in 
Fig. 2 (E,F).
www.nature.com/scientificreports/
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immunization decreasing the proportion of CCR5+ CD4+ TSCM which inhibits their infectivity, whilst decrease 
in α4β7 TSCM inhibits homing function of CD4+ CCR5 T cells.
Plasma CC chemokine upregulation and CD4+ T cell CCR5 co-receptor downmodulation. CC 
chemokines and A3G have been recognised to be important components of non-cognate or innate immunity. 
Hence, the 3 CC chemokines, CCR5 coreceptors of HIV-1 and the restriction factors A3G and Tetherin were 
studied in 42 blood samples from vaccinees and 12 placebos. Demonstrating induction of HSP70 suggested that 
the 3 CC chemokines may be upregulated23–25, 48 and these were studied in plasma by the Luminex bead assay, 
which showed significant increase in MIP-1β from 34.6 ± 2.59 pg/ml before to 39.1 ± 3.27 pg/ml, (p = 0.025) 2 
weeks after the final immunization (Fig. 5B). MIP-1α and RANTES showed no significant change (Fig. 5A,C). 
In contrast CCR5 expression assayed by flow cytometry (Fig. 5D,E) was decreased from 6.92 ± 0.45 before 
to 6.43 ± 0.41 2 weeks and 5.99 ± 0.49 28 weeks after the final immunization, the latter reaching significance 
(p = 0.013, Fig. 5E). The vaccinees showed significantly lower CCR5 coreceptors than the placebo controls at 
week 2 after the final immunization (p = 0.042, Fig. 5F). Furthermore, significant inverse correlation was found 
between CCR5 and RANTES as well as MIP-1α at week 28 after the last immunization (p = 0.01, Fig. 5G,H). The 
results are consistent with the increase in CC chemokines early after vaccination, followed by downmodulation 
of CCR5.
Upregulation of APOBEC3G (A3G) and Tetherin following immunization. We have then stud-
ied the anti-viral restriction factors, A3G and tetherin, which are upregulated by iHSP7027, 30. A3G exerts 
intra-cellular anti-viral activity, so any HIV gaining entry into CD4+ T cells may then be inhibited. An impor-
tant additional function of HSP70 is that it inhibits Vif- mediated ubiquitination and degradation of A3G, 
thereby retaining its function30. A3G mRNA assayed by RT-PCR showed significant fold-increase at week 2 
(9.6 ± 0.7, p = 0.013) and at week 28 (10.2 ± 1.01, p = 0.006), compared with pre-immunization baseline level 
(7.4 ± 0.65, Fig. 6A, n = 42). A3G protein was then examined by flow cytometry following intracellular staining 
with anti-A3G antibodies. Significant upregulation of A3G protein expressing cells was found in CD4+ T cells 
(37.6 ± 1.9%, p = 0.017, Fig. 6B) and CD4+ CD45RO+ memory T cells (37.8 ± 2.3% p = 0.03, Fig. 6C) at week 
2 after final immunization, compared with the pre-immunization samples (CD4+ T cells, 33.9 ± 1.5%). CD4+ 
CD45RO− naïve T cells were also increased at week 2 (p = 0.05, Fig. 6D). Although higher levels of A3G protein 
Figure 4. The effect of vaccination on inducible HSP70 in CD4+ TSCM and DC before and 28 weeks after 
immunization. (A) CD4+ TSCM, (B) HSP70 in CD4+ TSCM, (C) HSP70 in DC, (D) membrane associated 
(ma)IL-15 in DC. (A–D) Assays were performed on cells from the same vaccinees (n = 11). (E) Gating strategy 
used to identify DC. (F) Flow cytometry identifying HSP70 and IL-15 in DC, and HSP70 in TSCM. (G) The 
effect of stimulating CD4+ TSCM with microbial (m) HSP70 before and (H) after immunization. (I) The effect 
of dose dependent inhibition of HSP70 with PES in unstimulated and microbial (m)HSP70 stimulated CD4+ 
TSCM; *p value = 0.02, when compared with the untreated (0) µM of cells. (J) The effect of stimulating CD4+ 
TSCM with HIVgp140, compared with unstimulated cells on IFN-γ, IL-2 and IL-17 (n = 10 samples from 
different subjects).
www.nature.com/scientificreports/
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were observed at week 28 in CD4+ T cells, CD4+ CD45RO+ memory and CD4+ CD45RO− naive T cells, these 
failed to reach significant levels (Fig. 6B–D). The gating strategy is presented in Suppl. Fig. 4.
A3G protein production was further examined by Western blotting of PBMC lysates, which showed 
stronger bands 2 weeks after immunization and were maintained at least up to 28 weeks compared with the 
pre-immunization bands (Fig. 6E), representative blots from 2 immunized subjects). Two bands were seen, of 
which the upper was stronger than the lower, which is likely to be a breakdown product of the 44kDa upper band. 
Comparative Western blots in PBMC lysates from placebos showed only a slight increase in A3G protein at week 
2 and 28, compared with the pre-immunization bands (Fig. 6E).
A comparison of A3G in PBMC from the vaccinated with those from placebo showed an increase in A3G 
protein in CD4+ and CD45RO+ memory and CD45RO− naive T cells in the vaccinees (Fig. 6F–I) but significant 
levels were reached only in the CD4+ CD45RO− naïve T cells (Fig. 6H). These results suggest that whilst the 
vaccinees showed significant increase in A3G compared with the pre-immunization samples, comparison with 
placebos also yielded higher levels in the vaccinees, though not all reached significance. As Alum was used in the 
controls for the 3rd and 4th treatment and Alum alone induces HSP70 as a stress response, which upregulates 
IL-15, IL-15Ra45 and in turn A3G26, this may account for the above findings in the placebo.
From previous studies we assumed that either specific HIV-1 antigens in the vaccine or HSP70 or both 
activated CD4+ T cells and induced A3G. To this end, we re-stimulated PBMC from the pre- and both 
post-immunization PBMC in vitro with 10 µg/ml HIV gp140, cultured for 3 days and intracellular A3G was 
assayed in the CD4+ T cell subsets. Re-stimulation increased significantly only CD4 CD45RO+ CCR7− effector 
memory T cells at week 2 from 59.7 to 62.3% (p = 0.048, Supl. Fig. 5D), but not the CD4+ CD45RO+ or the 
CCR7+ central memory T cells (Supl. Fig. 5B,C). These results are consistent with the stress agent and not HIV 
antigen stimulating memory and central memory T cells.
We have then examined Tetherin, another HIV restriction factor by RT-PCR in the pre- and post- immuniza-
tion blood samples. Tetherin mRNA showed a small but significant increase in the vaccinees, at 2 weeks after the 
last immunization, compared with the pre-immunization samples (p = 0.047, Fig. 6I), suggesting a vaccination 
specific effect. Surprisingly, there was no significant difference in Tetherin between the immunized and placebo 
groups (Fig. 6J), which is likely to be due to Alum used in the placebos.
Figure 5. The effect of vaccination on production of CC chemokines and CCR5 in CD4+ T cells, 2 and 28 
weeks after the last immunization. (A) MIP-1α in pg/ml, (B) MIP-1β in pg/ml, (C) RANTES in ng/ml, all from 
different subjects (D) Representative flow cytometry of (E) proportion of CCR5 in CD4+ T cells before and 
after immunization(%), (F) proportion of CCR5 in vaccinated, compared with the placebo group. (G) Inverse 
correlation between CD4 CCR5+ T cells and RANTES or (H) MIP-1α; Immunized (n = 42) and placebo 
(n = 12).
www.nature.com/scientificreports/
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Figure 6. The restriction factors A3G and Tetherin 2 and 28 weeks after immunization. (A) A3G mRNA 
expression in PBMC examined by RT-PCR, (B) intracellular A3G in CD4+ T cells, (C) CD4+ CD45RO+ 
memory and (D) CD4+ CD45RO− naïve T cells were all studied by flow cytometry. (E) Western blots of PBMC 
lysates from 2 representative vaccines and 2 placebo controls; the blots were trimmed above about 50 kD and 
below 40 kD. (F) A3G in vaccinees was compared with the placebo groups at 2 weeks in CD4+ (G), CD45RO+ 
(H) CD45RO− T cells. (I) Tetherin mRNA was tested in PBMC before, 2 and 28 weeks after completion of 
immunization and (J) in vaccinees compared with placebos. Immunized (n = 42) placebo (n = 12, all from 
different subjects).
Figure 7. Correlation studies between RANTES, MIP-1α and MIP-1β CC chemokines and A3G mRNA 
showed significant direct correlation between them 2 weeks post-immunization (A,B,C), but was not 
maintained by 28 weeks (D–F); analysed by Spearman rank correlation coefficient; (n = 42 all from different 
subjects).
www.nature.com/scientificreports/
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Interestingly, significant correlation was found between A3G mRNA, an innate intracellular restriction factor 
and RANTES (r = 0.329, p = 0.033), MIP-1α (r = 0.333, p = 0.031) and MIP-1β (r = 0.423, p = 0.005), extracellu-
lar innate factors downregulating CCR5. This was seen at week 2 (Fig. 7A–C), but not week 28 after immunization 
(Fig. 7D–F). These results are consistent with our earlier data that the 3 CC chemokines may induce upregulation 
of A3G by activating CCR526 and this effect is induced early after immunization. Furthermore, they show correla-
tion between two innate factors, which are involved in pre- and post-entry inhibition of HIV-1.
Discussion
A robust immunological memory is critical for the function of any vaccine and has been inadequate in the RV144 
vaccine. The efficacy of HIV-1 acquisition decreased from 60% in the 1st year, to 36% in the 2nd and 32.3% in the 
3rd year1, despite expressing significant Env-specific CD4+ CD45RO+ CCR7− effector memory T cells4. This led 
us to examine TSCM cells reported in mice, NHP and humans9, 10, but this is the first report in vaccination. The 
proportion of CD4+, CD45RO−, CD62L+ CCR7+ CD95+ TSCM cells demonstrated by polychromatic markers 
was 2.33 ± 0.27% in the pre-immunized CD4+ T cells. Although it increased significantly after the last vaccination 
to 3.12 ± 0.36% (p = 0.018), this constituted a small proportion of self-replicating CD4+ T cells. An important 
finding was an increase in CD122 expressing CD4+ TSCM cells 28 weeks after the last immunization (p = 0.001). 
CD122 is a marker of the common IL-2 and IL-15 β chain receptor, the former being expressed by TSCM9 and the 
latter is induced in CD4+ T cells by iHSP70 following activation of ma IL-15 in DC40, 45. This is consistent with the 
paradigm that stress agents, to which the CD4+ TSCM cells are exposed, may regenerate their homeostatic pool 
by increasing maIL-1540, 41 and its receptor, thereby maintaining their prolonged function (over 10 years), as was 
demonstrated by genetically modified TSCM49.
CD4+ TSCM in HIV infection had been shown to harbour HIV and they play an important role in HIV 
persistence and latent HIV-1 reservoir42, 50. TSCM cells expressing CCR5 coreceptors of HIV-1 were significantly 
downregulated, thereby decreasing the infectivity of CD4+ TSCM. The R4 HIV-1 coreceptor CXCR4 expressing 
cells were not affected. Thus, 2 types of CD4+ TSCM cells were elicited by vaccination. CD122+ TSCM cells were 
upregulated, whilst CCR5+ TSCM were downregulated most likely by canarypox acting as a stress stimulating 
vector inducing HSP70. Homing of CCR5+ CD4+ T cells to mucosal tissues of the gut is mediated by α4β7 integ-
rin. As immunization decreased the proportion of α4β7 and CCR5 subsets of TSCM, homing to mucosal tissues 
and availability of TSCM cells for infection will diminish. Indeed, TSCM are not found in mucosal tissues but are 
located in lymph nodes10. The HIV-1 restriction factor A3G subset of TSCM was significantly increased, which 
with the decreased expression of CCR5+ and α4β7+ subsets of TSCM will lead to greater inhibition of HIV-1 
replication.
Vaccination in the RV144 clinical trial elicited iHSP70, which is the hallmark of cellular stress43, 44 and is likely 
to be involved in the mechanism of TSCM and innate immunity. HSP70 elicits CC chemokines, which downmod-
ulate CCR522–25, and increases A3G restriction factors26, as well as CD4+TSCM cells. Furthermore, HIV-1 virions 
carry a large number of host-derived antigens from previously infected cells, of which HSP7051 is expressed in 
high concentration, comparable to that of HIV pol protein. Thus, following exposure to HIV-1 infection the con-
stitutive HSP70 in HIV virions may boost CD4+ TSCM, CC chemokines and A3G mediated inhibition of HIV-1 
or SIV replication. This is consistent with the effect of iHSP70, exogenous mHSP70 or other stress agents inducing 
CD4+ TSCM. Treatment with PES, a small molecular inhibitor of iHSP70 function, inhibited CD4+ TSCM, sug-
gesting that iHSP70 is involved in induction of CD4+ TSCM.
We suggest in addition to the established sequential CD4+ memory pathway I TSCM →CMC →EMC9, 10 a 
novel 2nd innate immune pathway of CD4+ T cells (Supl. Fig. 6). The innate pathway consists of CD4+ TCSM 
generated subsets showing upregulation of IL2/IL-15 receptor expressing cells (CD122) and A3G TSCM cells, 
whereas the CCR5 and α4β7 subsets are downregulated. The overall trend of pre- and post-immunization 
between CD4+ TSCM and its subsets suggest that immunization favours HIV-1 inhibitory functions of TSCM, 
by increasing CD122 and A3G, whilst decreasing CCR5 and α4β7 expressing memory stem cells and the corre-
sponding innate immunity.
In the RV144 samples significant increase in plasma MIP-1β within 2 weeks of vaccination was maintained 
28 weeks after the last immunization. This was associated with downmodulation of CCR5 by 2 weeks, reaching 
significance by 28 weeks. A3G mRNA and its protein, as well as Tetherin and potentially other restriction factors, 
were significantly upregulated in CD4+ and CD45RO+ memory T cells by 2 weeks and was confirmed by Western 
blots. Importantly, each of the 3 CC chemokines showed significant direct correlation with A3G mRNA, sug-
gesting that, they are likely to be stimulated by HSP70 activating CCR5 and/or TLR2 and TLR452, 53. Restriction 
factors are dependent on type 1 IFN-stimulating genes and their expression in PBMC correlates with a decrease 
in viral load in IFN-treated patients54. Indeed, we have demonstrated that stress agents elicit large number of type 
1 IFN induced genes40.
Stress induced CC chemokines reported here, elsewhere4, 22–24 and in the vaginal vaccination trial25 are con-
sistent with an increase in MIP-1α and MIP-1β one day after IM administration of ALVAC in macaques or in 
vitro treatment with human PBMC55. A longitudinal study with the Canary pox vector showed that systemic vac-
cination significantly upregulates MIP-1α and MIP-1 β, in addition to IL-1β, TNF-α and MCP-1 early during the 
eclipse period of HIV-1 infection55. A significant correlation of the CC chemokines with the early development of 
A3G makes it likely that the innate restriction factor might also be increased in the eclipse period. Furthermore, 
cellular stress induces significant increase of cytokines, such as IFN-γ, IL-12, IFN-α, IL-1β, IL-6 and TGFβ40, 45, 
some of which were also demonstrated in the canary pox studies55, and IFN-γ with IL-2 in the present investiga-
tion. These data support the proposed stress-mediated effect early and possibly in the eclipse period of the RV144 
vaccination trial.
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Downregulation of CCR5 in CD4+ T cells has emerged as a major factor since the finding that subjects with 
homozygous ∆32 bp CCR5 deletion are protected from HIV-1 infection11, 12. Decrease of CCR5 expression in 
CD4+ T cells of humans and NHP had now been demonstrated following alloimmunization14, mucosal vac-
cination25, systemic vaccination (the present data), elite controllers or non-progressors in adults18, 56, 57, and in 
children19. This mechanism is also seen in natural infection with SIV of sooty mangabeys17, 18 and gene based 
methods, such as stem cell transplantation58. Many of these diverse strategies involve CD4+ TSCM.
Paradoxically CD4+ TSCM cells may also function as an HIV-1 reservoir, possibly because they express low 
concentrations of virus restriction factors42, promoting long-term virus persistence. The dual functional effect of 
long-term memory and HIV-1 latency of TSCM and the differential effect of the 4 subsets of CD4+ TSCM might 
be involved in the waning efficacy of the vaccine. We postulate that the timing in upregulation of CD122 and A3G 
expressing cells, associated with a decrease in CCR5 and α4β7 CD4+ TSCM cells may be critical in the outcome of 
the balance between HIV-1 infectivity linked latency of TSCM and potentially the beneficial long-term memory 
of TSCM59.
The overall analysis of cellular stress suggests the following mechanism.
1) Stress induces HSP70, which elicits NF-kB in DC and a series of phosphorylation signalling downstream in 
CD4+ memory T cells we have reported previously40, 53. 2) This induces CC chemokines, which downmodulates 
CCR5 co-receptors and inhibits pre-entry HIV-1. 3) Any HIV-1 virions, which escaped the pre-entry barrier may 
be inhibited post-entry by A3G and other restriction factors. 4) The adaptive immune phase, enhanced by innate 
immunity, plays a major role in inhibiting and eliminating any virus, which escaped the two early barriers by 
specific cytotoxic memory T cells, and B cell mediated antibodies2–5. The role of binding IgG antibodies, ADCC 
and the counteracting IgA antibodies are critical2–5. 5) Prolonged immune memory and innate responses may 
be mediated by a balance between increased CD122 and A3G, and decreased CCR5 and α4β7 expressing CD4+ 
TSCM pathways. We suggest that the dual stem cell memory interacting with the dual innate immunity may con-
tribute to effective protection of HIV-1 infection and maintenance of prolonged immune memory.
Methods
Study Oversight. The protocol was approved by the ethics committees of the Ministry of Public Health, 
the Royal Thai Army, Mahidol University, and the Human Subjects Research Review Board of the U.S. Army 
Medical Research and Materiel Command. It was also independently reviewed and endorsed by the World Health 
Organization1. The ethical approval and relevant documents for the RV144 trial is in the public domain (reg-
istered at www.ClinicalTrials.gov, NCT00223080) and published in the first study report1. All volunteers were 
asked consent to participate in the trial and the Test of Understanding (TOU) was used to determine whether 
volunteers understood the trial and the pre-trial information regarding HIV, experimental vaccines, and their 
rights as a volunteer.
The present study is part of the RV144 phase III clinical trial, which was a community-based, randomized, 
multicentre, double-blind, placebo-controlled efficacy trial1. We obtained samples from 73 vaccinated subjects 
(38 male and 35 female) and 19 placebo controls (9 male, 10 female). Thai men and women were between 18 
and 30 years of age and they were not infected with HIV before or after the trial. They were recruited from the 
community without regard to HIV risk (i.e., community risk). Women were counselled to practice effective con-
traception until 3 months after the last vaccination; pregnant and breast-feeding women were excluded1. For the 
TSCM studies we used 35 vaccinated and 7 placebo controls and for the innate immunity studies we used 42 vac-
cinated subjects and 12 placebo controls. In both cohorts there were similar number of male and female subjects.
PBMC and plasma samples. Blood was withdrawn by venepuncture, PBMC and plasma were prepared 
using 8 ml sodium citrate Vacutainer® Cell preparation tubes (CPT™). Separated PBMC were cryopreserved 
in RPMI medium and plasma stored at −80 °C1. Vaccine and the immunization procedure was published pre-
viously1. Samples collected before start of immunization, and 2 and 28 weeks after completion of immunization 
(week 24) were used to analyse the concentrations of three CC chemokines, TSCM, expression of cell surface 
CCR5 and intracellular APOBEC3G, Tetherin and HSP70. All the data presented are from different immunized 
or control subjects and all the comparative assays of TSCM – CM – EM - and naïve cells are from the same 
subjects.
Assay of CD4+ and CD8+ TSCM and inhibition of the CD4+TSCM cells by PES. The pre-immunized 
and post-immunized samples were then analysed in parallel in each assay. The viability of thawed cells was 
checked by trypan blue exclusion and was greater than 95%. Phenotypic expression of CD4 and CD8 memory 
TSCM cells were identified by polychromatic flow cytometry, using antibodies to CD45RO, central memory 
cells by expressing CD4+ CD45RO+ CCR7+ and effector memory cells by CD4+CD45+CCR7− cells39. CD4 or 
CD8 TSCM cells were identified in PBMC by antibodies to CD45RO (PE-Cy7), CD62L (APC-Cy-7), CCR7 
(PerCP) and CD95 (FITC). All conjugated antibodies were purchased from Biolegend UK. In addition, antibod-
ies to CD122, CCR5, CXCR4 (PE-conjugated, all from Biolegend) and α4β7 (clone Act-1, obtained from NIBSC, 
Potters Bar, UK) were used to define TSCM subsets. 5 × 105 PBMC were incubated with a combination of fluo-
rochrome conjugated antibodies (Biolegend UK) for 30 min at 4 °C, washed and then analysed by the FACScanto 
II flow cytometer, using DIVA software. A3G expression in TSCM was then assayed by intra-cellular staining as 
described below.
To determine the specificity of HSP70 in stimulating TSCM, dose dependent inhibition was carried out with 
the HSP70 inhibitor, 2-phenylethynesulfonamide (PES, Calbiochem, Merck, UK). PBMC were stimulated with 
mHSP70 (20 µg/ml) in the presence of various concentrations (5–100 µM) of PES. After 5 day culture, TSCM were 
analysed by flow cytometry.
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Assay of inducible HSP70 (iHsp70) in DC. DC were analysed by flow cytometry and defined as live, 
lineage negative, HLA DRhigh cells. PBMC were surface stained with lineage cocktail antibodies (conjugated with 
APC), against CD3, CD14, CD16, CD19, CD20, CD56 and HLA-DR PE Cy7 (clone L243), both from Biolegend 
(cat 348803) and fixable viability dye e780 (eBioscience). Cells were then fixed, permeabilised with the intra-
cellular fixation and permeabilization buffers (eBioscience) and then stained with iHSP70 PE (clone C92F3A 
Stressgen) or an isotype control antibody.
Assay of TSCM cytokines by intracellular staining. CD4+ TSCM produced cytokines, IFN-γ, IL-2, 
IL-17 and TNFα were detected by intracellular staining the cells with PE-conjugated antibodies (Biolegend) fol-
lowing restimulation of cells with PMA, after 4 days in vitro culture of cells in the presence 10 µg/ml of HIVgp140 
antigen (NIBSC, Potters Bar, UK).
Assay of RANTES, MIP-1α, and MIP-1β in plasma. Quantitation of RANTES, macrophage inflamma-
tory protein 1α (MIP-1α), and MIP-1β (CCL-5, CCL-3, and CCL-4, respectively) was carried out by a Luminex 
bead assay using Fluorokine multianalyte profiling (MAP) kits (R&D, Oxford, United Kingdom), as described 
previously25.
Flow cytometry analysis of cell surface expression of CCR5 on CD4+ T cells. CCR5 expression 
on CD4+ T cells was identified by incubating 1 × 106 PBMCs with antibodies specific to CCR5 (BD Biosciences, 
United Kingdom). After 20 min the cells were washed and analysed by flow cytometry, and live cells were gated 
and expressed as the proportion of CCR5 on CD4+ T cells.
Preparation of RNA and cDNA. PBMC (2 × 106) were thawed from cryo-preserved samples into RPMI 
1640 medium supplemented with 10% FCS. After centrifugation at 500 g for 5 min, the cell pellets were washed 
with PBS. RNA was isolated using a Total RNA Isolation Kit (Promega, UK), quantified using the spectrophotom-
eter (GeneQuant II, Pharmacia Biotech), and cDNA was generated from RNA by using the Reverse Transcription 
System (Promega), according to the manufacturer’s instructions. Cryo-preserved PBMC isolated from a healthy 
donor (National Blood Service) was thawed and RNA was prepared as the internal control.
Real-time PCR for A3G and tetherin mRNA. Relative amount of A3G mRNA was quantified by 
real-time PCR (ABI Prism 5700) using the PlatinumSYBR green qPCR SuperMix-UDG without ROX (Invitrogen 
Life Technologies). The primers for A3G and GAPDH were described elsewhere26. When assaying the samples 
for A3G and GAPDH, an internal control was included in each run under the same conditions and the relative 
amount of A3G in the samples was determined by comparing with the Ct values of the internal control sample. 
The results were expressed as the fold increase of internal control. Tetherin/bst2 mRNA levels were measured 
using an ABI primer/probe qRT-PCR set and calculated relative to GAPDH mRNA on an ABI 6700 machine.
Investigations of A3G protein by flow cytometry. Intracellular A3G protein expression on CD4+ T 
cells was assayed by intracellular staining with anti-A3G MAbs, as described elsewhere35. MAbs to A3G and iso-
type control antibody from ABDserotec were conjugated with fluorescein isothiocyanate (FITC) using a LYNX 
rapid fluorescein antibody conjugation kit (ABD Serotec, Oxford, United Kingdom). Optimal concentration was 
determined by serial dilutions and the reproducibility was tested by staining the thawed PBMC from the same 
subjects at different times; variations were less than 5%.
Human CD4+ memory and naïve T cell subsets were identified using antibodies to CD45RO as described 
above. After cell surface staining the cells (2 × 105) were washed and fixed with a fixation buffer for 3 min (eBiosci-
ence, Insight Biotechnology, London, United Kingdom), followed by treatment with the permeabilization buffer 
(eBioscience). FITC-conjugated A3G antibody (10 u l at 10 μg/ml) was added to the cell pellets, and following 
30 min of incubation, the cells were washed and analyzed by flow cytometry on a FACSCanto II flow cytometer 
(BD Biosciences) using FACSDiva software. To assay the effect of specific antigen re-stimulation on A3G pro-
duction, aliquots of 200 µl PBMC (3 × 106/ml) were incubated in RPMI medium supplemented with 10% FCS, 
2 mM glutamine and 100 µg/ml of penicillin and streptomycin, in the presence or absence of 10 µg/ml of HIV-1MN 
gp120. After 3 day culture, cells were assayed for A3G expression by flow cytometry.
Statistical analysis. All results are expressed as mean (±sem). The non-parametric paired t test (Wilcoxon 
signed rank test) was used for analysis of significance between pre- and post-immunized samples. Mann Whitney 
test was used to analyse the significance between vaccine and placebo groups. Spearman rank or Pearson cor-
relation coefficient was applied for analyses of correlations. Probability value (p) < 0.05 was considered to be 
significant.
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